Inhibitors in AKTion: ATP-competitive vs allosteric.
Loading...
Embargo End Date
ICR Authors
Authors
Lazaro, G
Kostaras, E
Vivanco, I
Kostaras, E
Vivanco, I
Document Type
Journal Article
Date
2020-06-30
Date Accepted
2020-04-20
Abstract
Aberrant activation of the PI3K pathway is one of the commonest oncogenic events in human cancer. AKT is a key mediator of PI3K oncogenic function, and thus has been intensely pursued as a therapeutic target. Multiple AKT inhibitors, broadly classified as either ATP-competitive or allosteric, are currently in various stages of clinical development. Herein, we review the evidence for AKT dependence in human tumours and focus on its therapeutic targeting by the two drug classes. We highlight the future prospects for the development and implementation of more effective context-specific AKT inhibitors aided by our increasing knowledge of both its regulation and some previously unrecognised non-canonical functions.
Citation
Biochemical Society transactions, 2020, 48 (3), pp. 933 - 943
Source Title
Publisher
PORTLAND PRESS LTD
ISSN
0300-5127
eISSN
1470-8752
Collections
Research Team
Molecular Addictions